AARTI DRUGS LIMITED
|
PART I(` in Lakhs ) |
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2012 |
|
|
Quarter Ended |
Financial Year Ended |
Consolidated |
Sr. |
Particulars |
31st Mar 2012 |
31st Dec 2011 |
31st Mar 11 |
31s Mar 2012 |
31st Mar 2011 |
31st Mar 2012 |
31st Mar 2011 |
No. |
|
(Audited) |
(Audited) |
(Audited) |
(Audited) |
(Audited) |
(Audited) |
(Audited) |
|
|
|
|
|
|
|
|
|
1 |
Income from Operations |
|
|
|
|
|
|
|
|
(a) Net Sales / Income from Operations |
19,818 |
15,509 |
14,336 |
65,154 |
49,642 |
65,926 |
50,105 |
(Net Of Excise Duty & Sales Tax) |
|
|
|
|
|
|
|
|
(b) Other Operating Income |
282 |
3 |
1 |
291 |
8 |
610 |
16 |
|
Total income form operations (net) |
20,100 |
15,512 |
14,337 |
65,444 |
49,650 |
66,536 |
50,120 |
2 |
Expenditure |
|
|
|
|
|
|
|
|
(a).Cost of materials consumed |
10,465 |
8,660 |
7,985 |
38,189 |
27,300 |
38,413 |
27,666 |
|
(b).Purchase of stock-in-trade |
2,173 |
1,669 |
1,849 |
7,735 |
8,421 |
7,336 |
7,633 |
|
(c).Changes in inventories of finished goods, |
1,489 |
353 |
352 |
(383) |
(1,618) |
(107) |
(1,870) |
|
work-in-progress and stock-in-trade |
|
|
|
|
|
|
|
|
(d). Employee benefits expense |
718 |
523 |
476 |
2,335 |
1,787 |
2,485 |
2,147 |
|
(e). Depreciation and amortisation expense |
544 |
468 |
474 |
2,065 |
1,774 |
2,200 |
1,911 |
|
(f). Other expenses |
2,679 |
2,591 |
2,057 |
10,053 |
7,490 |
10,594 |
7,831 |
|
Total expenses |
18,069 |
14,264 |
13,193 |
59,994 |
45,155 |
60,922 |
45,318 |
3 |
Profit from Operations before Other Income, |
|
|
|
|
|
|
|
|
finance costs and exceptional items (1-2) |
2,031 |
1,248 |
1,143 |
5,450 |
4,495 |
5,614 |
4,803 |
4 |
Other Income |
0 |
- |
- |
- |
- |
|
|
5 |
Profit from ordinary activities before finance cost |
2,031 |
1,248 |
1,143 |
5,450 |
4,495 |
5,614 |
4,803 |
|
and exceptional items (3+4) |
|
|
|
|
|
|
|
6 |
Finance costs (interest) |
650 |
574 |
409 |
2,082 |
1,348 |
2,267 |
1,492 |
7 |
Profit from ordinary activities after finance cost |
|
|
|
|
|
|
|
|
but before Exceptional Items (5+6) |
1,381 |
674 |
734 |
3,368 |
3,147 |
3,347 |
3,311 |
8 |
Exceptional Items |
- |
- |
- |
- |
- |
116 |
- |
9 |
Profit from Ordinary Activities before Tax (7+8) |
1,381 |
674 |
734 |
3,368 |
3,147 |
3,231 |
3,311 |
10 |
Tax Expenses (Includes) |
454 |
193 |
105 |
1,006 |
900 |
975 |
961 |
|
Provision for Taxation |
390 |
118 |
64 |
790 |
650 |
800 |
792 |
|
Provision for Deferred Taxation |
64 |
74 |
41 |
216 |
250 |
176 |
169 |
11 |
Net profit from ordinary Activities after Tax |
927 |
481 |
629 |
2,362 |
2,247 |
2,256 |
2,350 |
12 |
Extraordinary Item (net of tax expenses ) |
- |
- |
- |
|
- |
- |
- |
|
Tax Provisionof Earlier Year |
86 |
|
|
86 |
|
86 |
(4.88) |
13 |
Net Profit for the period (11+12) |
842 |
481 |
629 |
2,276 |
2,247 |
2,170 |
2,355 |
|
Adjustments: |
|
|
|
|
|
|
|
|
(a) Adjustments on Consolidation |
|
|
|
- |
- |
(8) |
(9) |
14 |
Share of profit/(loss) of associates |
- |
- |
- |
- |
- |
8 |
30 |
15 |
Net profit after taxes minority interest and share of |
|
|
|
|
|
|
|
|
profit /(loss) of associates (13+14+15) |
842 |
481 |
629 |
2,276 |
2,247 |
2,169 |
2,376 |
16 |
Paid-up Equity Share Capital of `10/- each. |
1,211 |
1,211 |
1,211 |
1,211 |
1,211 |
1,211 |
1,211 |
17 |
. Reserves & Surplus (excluding revaluation reserves) |
- |
- |
- |
16,013 |
14,441 |
16,572 |
15,105 |
18.i |
Earning per share |
|
|
|
|
|
|
|
|
(of ` /- each) (not annualised) |
|
|
|
|
|
|
|
|
(a) Basic & Diluted |
7.66 |
3.97 |
5.19 |
19.50 |
18.56 |
18.63 |
19.58 |
PART II
A |
PARTICULARS OF SHAREHOLDING |
|
|
|
|
|
1 |
Public shareholding |
|
|
|
|
|
|
-Number of Shares |
5,379,245 |
5,469,811 |
5,569,613 |
5,379,245 |
5,569,613 |
|
-Percentage of Total Shareholding |
44.43 |
45.17 |
46.00 |
44.43 |
46.00 |
2 |
Promoters & Promoter Group shareholding |
|
|
|
|
|
|
a) Pledged/Encumbered |
|
|
|
|
|
|
- Number of Shares |
Nil |
Nil |
Nil |
Nil |
Nil |
|
-Percentage of shares(as a % of the |
Nil |
Nil |
Nil |
Nil |
Nil |
|
total shareholding of promoter and promoter group) |
|
|
|
|
|
|
-Percentage of shares( as a % of the |
Nil |
Nil |
Nil |
Nil |
Nil |
|
total Share capital of the company) |
|
|
|
|
|
|
b) Non-encumbered |
|
|
|
|
|
|
- Number of Shares |
6,729,305 |
6,638,739 |
6,538,937 |
6,729,305 |
6,538,937 |
|
-Percentage of shares(as a % of the total Shareholding |
100 |
100 |
100 |
100 |
100 |
|
of promoter and promoter group) |
|
|
|
|
|
|
-Percentage of shares( as a % of the total |
55.57 |
54.83 |
54.00 |
55.57 |
54.00 |
|
Share capital of the company) |
|
|
|
|
|
B |
INVESTOR COMPLAINTS |
Quarter ended 31st March, 2012 |
|
|
|
|
Pending at the begining of the quarter |
0 |
|
|
|
|
Received during the quarter |
3 |
|
|
|
|
Disposed of during the quarter |
3 |
|
|
|
|
Remaining unresloved at the end of the quarter |
0 |
|
|
|
STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2012 ( ` in lacs)
|
|
|
|
|
|
|
|
Particulars |
For the year ended |
Consolidated |
|
|
|
31/03/2012 |
31/03/2011 |
31/03/2012 |
31/03/2011 |
A |
EQUITY AND LIABILITIES |
|
|
|
|
1 |
Sharholder's funds |
|
|
|
|
|
(a) Share Capital |
1,211 |
1,211 |
1,211 |
1,211 |
|
(b) Reserves and surplus |
16,013 |
14,441 |
16,572 |
15,105 |
2 |
Non-current liabilities |
|
|
|
|
|
(a) Long - term borrowings |
6,692 |
7,434 |
6,692 |
7,634 |
|
(b) Deferred tax liabilities (net) |
2,446 |
2,230 |
2,447 |
2,271 |
|
(c) Other long - term liabilities |
758 |
757 |
850 |
909 |
|
(d) Long - term provisions |
131 |
- |
- |
- |
|
Sub - total - Non - current liabilities |
10,027 |
10,421 |
9,989 |
10,814 |
3 |
Current liabilities |
|
|
|
|
|
(a) Short - term borrowings |
18,982 |
14,723 |
20,525 |
16,522 |
|
(b) Trade payables |
9,065 |
7,736 |
6,970 |
5,562 |
|
(c) Other current liabilities |
2,806 |
2,416 |
2,847 |
2,438 |
|
(d) Short - term provisions |
499 |
641 |
542 |
694 |
|
Sub - total - current liabilities |
31,715 |
25,517 |
31,188 |
25,216 |
|
TOTAL- EQUITY AND LIABILITIES |
58,966 |
51,589 |
58,960 |
52,346 |
|
|
|
|
|
|
B |
ASSETS |
|
|
|
|
1 |
Non-current assets |
|
|
|
|
|
(a) Fixed assets |
26,487 |
23,458 |
27,648 |
25,616 |
|
(b) Goodwill on consolidation |
- |
- |
206 |
206 |
|
(c) Non - current investments |
2,477 |
2,461 |
669 |
528 |
|
(d) Long - term loans and advances |
105 |
863 |
224 |
961 |
|
Sub - total - Non - current assets |
29,068 |
26,782 |
28,748 |
27,311 |
|
|
|
|
|
|
2 |
Current assets |
|
|
|
|
|
(a) Inventories |
9,277 |
8,316 |
9,746 |
9,183 |
|
(b) Trade receivables |
17,099 |
12,583 |
16,289 |
12,134 |
|
(c) Cash and cash equivalents |
456 |
359 |
494 |
527 |
|
(d) Short - term loans and advances |
2,470 |
2,276 |
2,142 |
1,871 |
|
(e) Other non - current assets |
596 |
1,273 |
1,539 |
1,320 |
|
Sub - total - current assets |
29,897 |
24,807 |
30,212 |
25,035 |
|
|
|
|
|
|
|
TOTAL - ASSETS |
58,966 |
51,589 |
58,960 |
52,346 |
|
|
|
|
|
|
Notes : |
|
|
|
|
1. The above audited financial results, were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 25th May, 2012. |
2. The Board of Directors has recommended Final Dividend of Rs. 3/-per share on 1,21,08,550 Equity shares of Rs. 10/- eachfully paid-up for the Financial year 2011-12. |
3. Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business. |
4. Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary has been approved but not effective for pending certified copies of the Bombay High Court order. |
5. Figures for the previous period have been regrouped or rearranged wherever necessary. |
|
|
|
|
|
|
|
|
|
For and on behalf of the Board |
|
For AARTI DRUGS LIMITED |
|
|
|
|
|
|
|
|
|
|
|
|
|
Place : Mumbai |
MR. HARSHIT M. SAVLA |
|
Date: 25th May, 2012 |
(JT. MANAGING DIRECTOR) |
|